Silverarc Capital Management LLC Buys New Holdings in Delcath Systems, Inc. (NASDAQ:DCTH)

Silverarc Capital Management LLC purchased a new stake in Delcath Systems, Inc. (NASDAQ:DCTH - Free Report) in the fourth quarter, according to its most recent disclosure with the Securities & Exchange Commission. The fund purchased 155,325 shares of the company's stock, valued at approximately $1,870,000. Silverarc Capital Management LLC owned about 0.49% of Delcath Systems as of its most recent SEC filing.

Other institutional investors and hedge funds have also added to or reduced their stakes in the company. Quantbot Technologies LP bought a new position in shares of Delcath Systems in the fourth quarter worth about $66,000. Barclays PLC bought a new position in Delcath Systems in the 3rd quarter worth approximately $104,000. Jane Street Group LLC acquired a new position in Delcath Systems during the 3rd quarter worth $110,000. Private Advisor Group LLC bought a new position in Delcath Systems in the 4th quarter valued at $153,000. Finally, Charles Schwab Investment Management Inc. acquired a new stake in shares of Delcath Systems in the 4th quarter valued at $156,000. Institutional investors and hedge funds own 61.12% of the company's stock.

Wall Street Analyst Weigh In

DCTH has been the topic of several research reports. HC Wainwright upped their price target on Delcath Systems from $22.00 to $24.00 and gave the company a "buy" rating in a research note on Friday, March 7th. Craig Hallum boosted their price objective on Delcath Systems from $18.00 to $21.00 and gave the stock a "buy" rating in a report on Friday, January 17th. One research analyst has rated the stock with a hold rating and four have given a buy rating to the company's stock. According to MarketBeat, Delcath Systems has a consensus rating of "Moderate Buy" and a consensus target price of $22.75.

Delcath Systems Trading Up 0.4 %

Shares of NASDAQ:DCTH traded up $0.05 during midday trading on Friday, hitting $12.11. The company had a trading volume of 187,555 shares, compared to its average volume of 356,744. Delcath Systems, Inc. has a 12 month low of $5.12 and a 12 month high of $16.97. The firm has a fifty day simple moving average of $12.69 and a 200 day simple moving average of $12.40. The stock has a market cap of $404.87 million, a price-to-earnings ratio of -8.97 and a beta of 0.85.

Delcath Systems (NASDAQ:DCTH - Get Free Report) last issued its earnings results on Thursday, March 6th. The company reported ($0.11) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.10) by ($0.01). Delcath Systems had a negative return on equity of 338.16% and a negative net margin of 150.70%. The company had revenue of $15.10 million for the quarter, compared to the consensus estimate of $14.96 million. During the same quarter last year, the business posted ($0.48) EPS. Equities analysts forecast that Delcath Systems, Inc. will post -0.79 EPS for the current fiscal year.

Delcath Systems Company Profile

Delcath Systems, Inc, an interventional oncology company, focuses on the treatment of primary and metastatic liver cancers in the United States and Europe. The company's lead product candidate is HEPZATO KIT, a melphalan for injection/hepatic delivery system to administer high-dose chemotherapy to the liver while controlling systemic exposure and associated side effects.